X

Trial Profile

A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms ATTRACTION-05
Sponsors Ono Pharmaceutical

Most Recent Events

04 Jul 2023 Planned End Date changed from 1 Oct 2023 to 1 Mar 2024.
06 Jun 2023 First confirmatory results of N+C as postoperative adjuvant treatment, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
09 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com